Matulonis UA, et al. - Cabozantinib is a targeted kinase inhibitor with anti-ovarian cancer activity, researchers performed this open label, 1:1 randomized study of cabozantinib 60 mg orally (PO) daily vs weekly paclitaxel 80 mg/m² given 3 out of 4 weeks (NCT01716715) to 111 patients. Outcomes revealed comparable median PFS for cabozantinib and weekly paclitaxel, but compared to weekly paclitaxel, cabozantinib was associated with worse overall survival, event free survival and overall response rate. For recurrent ovarian cancer treatment, findings do not support cabozantinib given at this dose and schedule.